Aurobindo Gets Final USFDA Nod for pre-Surgery Sedation Drug

MarketMagnify provides you accurate tips related to the stock and share market with great accuracy percentile. For more information visit:- http://www.marketmagnify.com/aboutus.php

 

Aurobindo Pharma has received final approval from the USFDA to manufacture and market pre- surgery sedation injections Dexmedetomidine Hydrochloride. 

 

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Dexmedetomidine Hydrochloride Injection, 200 mcg (base)/2 mL (100 mcg (base)/mL) single-dose vials," Aurobindo Pharma said in a BSE filing today. 

 

The company said the approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug Precedex Injection, 200 mcg/2 mL, of Hospira Inc and this product is expected to be launched in the first quarter of next fiscal. 

 

The approved product has an estimated market size of USD 59.1 million for the 12 months ending January 2016 according to IMS, Aurobindo Pharma said.